Abstract
The present study reported the case of a patient with primary anaplastic large cell lymphoma (ALCL) occurring in the left major psoas. A 24-year-old male patient presented with a one-month history of left lower back pain, which had been exacerbated for 10 days prior to admission. Magnetic resonance imaging (MRI) scans revealed an enlarged major psoas muscle that protruded into the inguinal region. The presence of an intense soft tissue mass on MRI scans, as well as the results of fine-needle aspiration biopsy and immunohistochemical analysis of the mass, may help establish an early diagnosis, allowing for the appropriate treatment strategy to be initiated.
Introduction
Anaplastic large cell lymphoma (ALCL) is a rare non-Hodgkin lymphoma derived from T-cells, typically identified by the expression of the CD30 antigen. While ALCL commonly involves extranodal sites such as the skin, lungs, or liver, primary involvement of the skeletal muscle is exceptionally rare, occurring in only 0.1% of lymphomas.
A literature review of cases from 1950 to 2013 identified only eight previously reported instances of primary skeletal muscle CD30+ ALCL in English literature, making this the ninth reported case. A mass in the skeletal muscle—such as the psoas—often presents clinically and radiologically as a soft-tissue sarcoma (e.g., rhabdomyosarcoma). Because treatment protocols for sarcomas and lymphomas differ fundamentally, misdiagnosis can lead to ineffective surgical interventions or delayed chemotherapy. This report highlights the diagnostic roadmap required to distinguish this aggressive malignancy early.
Case Presentation
A 24-year-old male presented with a one-month history of left lower back pain. Magnetic Resonance Imaging (MRI) identified a large mass (15x7 cm) in the left major psoas muscle extending into the inguinal region. The mass displayed slightly higher signal intensity than normal muscle on T1-weighted images and intermediate signal intensity on T2-weighted images.
Following surgical resection of the psoas muscle, histopathological examination revealed neoplastic cell infiltration and irregular mitosis. Immunohistochemistry (IHC) was definitive, showing the tumor was CD30+ and LCA+, but negative for ALK, CD15, and EBV. This confirmed a diagnosis of ALK-negative ALCL. Laboratory tests also showed a significantly elevated lactate dehydrogenase (LDH) level of 1,958 U/l (normal range: 104–245 U/l), indicating high metabolic activity.
The patient was treated with an aggressive chemotherapy regimen: three cycles of bortezomib plus EPOCH, followed by one cycle of bortezomib plus hyper-CVAD. This approach successfully induced remission, which was sustained for six months post-discharge.
Discussion
ALCL is categorized into ALK-positive and ALK-negative subtypes. ALK-negative ALCL is generally more aggressive and typically affects older patients; its occurrence in a 24-year-old is particularly noteworthy.
Diagnosis remains a significant challenge. Fine-needle aspiration (FNA) can be inconclusive if "hallmark cells" are not captured in small samples. Therefore, IHC is essential for correct classification. Furthermore, despite the primary mass being localized to the muscle, the patient was classified as Stage IV due to rapid systemic spread to cervical, axillary, and inguinal lymph nodes, highlighting the systemic nature of ALK-negative variants.
MRI signatures can provide early clues. The observed signal intensities—slightly higher than muscle on T1 and intermediate on T2—help differentiate these lymphomas from other soft-tissue tumors, though they are not pathognomonic.
Conclusion
Primary skeletal muscle ALCL is a rare but critical differential diagnosis for soft-tissue masses. Combining MRI imaging with rigorous IHC analysis is vital for early diagnosis and the initiation of appropriate chemotherapy. Future work should focus on establishing standardized imaging criteria and molecular biomarkers to further streamline the diagnostic process and avoid unnecessary radical surgeries.
Summary updated